ResearchMoz

Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns

GBI Research
Published Date » 2014-03-13
No. Of Pages » 74
   
 GBI Research has released its pharma research: ‘Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns ’, which provides in-depth analysis of epilepsy market within the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of the market size for 2012, along with market forecasts to 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The value of the epilepsy market in the major developed markets amounted to an estimated $3.4 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 3.9% to reach $4.5...
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology
2.5 Pathophysiology
2.6 Co-morbidities/Complications
2.7 Diagnosis
2.8 Prognosis
2.9 Treatment Efficacy
2.10 Treatment Options
2.10.1 Ion Channel Modulators
2.10.2 GABA-ergic Facilitation
2.10.3 Excitatory Amino Acid Inhibitors
2.10.4 Synaptic Modulators
2.11 Non-pharmacological Management
2.11.1 Lobectomy and Lesionectomy
2.11.2 Ketogenic Diet and Modified Atkins Diet
2.11.3 Vagus Nerve Stimulation

3 Epilepsy Therapeutic Landscape
3.1 Overview
3.2 Lyrica (pregabalin)
3.3 Lamictal (lamotrigine)
3.4 Keppra (levetiracetam)
3.5 Zonegran (zonisamide)
3.6 Vimpat (lacosamide)
3.7 Aptiom/Zebinix (eslicarbazepine acetate)
3.8 Fycompa (perampanel)
3.9 Trobalt/Potiga (ezogabine/retigabine)
3.10 Banzel/Inovelon (rufinamide)
3.11 Comparative Efficacy and Safety of Marketed Products

4 Pipeline for Epilepsy Therapeutics
4.1 Overall Pipeline
4.2 Pipeline by Mechanism of Action
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Patient Enrolment and Clinical Trial Size
4.3.3 Clinical Trial Duration
4.4 Promising Pipeline Candidates
4.4.1 Brivaracetam – UCB
4.4.2 Ganaxolone – Marinus Pharmaceuticals

5 Epilepsy Therapeutics Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Major Developed Markets
5.1.2 The US
5.1.3 Top Five EU Countries
5.1.4 Japan
5.1.5 Canada
5.2 Drivers and Barriers
5.2.1 Drivers
5.2.2 Barriers

6 Deals and Strategic Consolidations
6.1 Deals Analysis
6.2 Research and Development Co-development Agreements
6.3 Research and Development Licensing Agreements

7 Appendix
7.1 Abbreviations
7.2 References
7.3 References for Heat Maps
7.4 Pipeline Products by Phase
7.4.1 Discovery
7.4.2 Preclinical
7.4.3 IND-filed and Phase 0
7.4.4 Phase I
7.4.5 Phase II
7.4.6 Phase III
7.4.7 Pre-registration
7.5 Market Forecasting Data Tables to 2019
7.5.1 Major Developed Markets
7.5.2 US
7.5.3 UK
7.5.4 France
7.5.5 Germany
7.5.6 Italy
7.5.7 Spain
7.5.8 Japan
7.5.9 Canada
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer

List of Tables

Table 1: Epilepsy Therapeutics, Global, Types of Seizures, 2013
Table 2: Epilepsy Therapeutics, Heat Maps for Efficacy and Safety of Marketed Products, References
Table 3: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Discovery), 2013
Table 4: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Preclinical), 2013
Table 5: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013
Table 6: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase I), 2013
Table 7: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase II), 2013
Table 8: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 9: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Pre-registration), 2013
Table 10: Epilepsy Therapeutics, Major Developed Markets, Market Forecast, 2012–2019
Table 11: Epilepsy Therapeutics, US, Market Forecast, 2012–2019
Table 12: Epilepsy Therapeutics, UK, Market Forecast, 2012–2019
Table 13: Epilepsy Therapeutics, France, Market Forecast, 2012–2019
Table 14: Epilepsy Therapeutics, Germany, Market Forecast, 2012–2019
Table 15: Epilepsy Therapeutics, Italy, Market Forecast, 2012–2019
Table 16: Epilepsy Therapeutics, Spain, Market Forecast, 2012–2019
Table 17: Epilepsy Therapeutics, Japan, Market Forecast, 2012–2019
Table 18: Epilepsy Therapeutics, Canada, Market Forecast, 2012–2019

List of Figures

Figure 1: Epilepsy Therapeutics, Epidemiology, Major Developed Markets, 2012
Figure 2: Epilepsy Therapeutics, Major Developed Markets, Approved Anti-epileptic Drugs, 2013
Figure 3: Epilepsy Therapeutics, Lyrica, Global, Revenue ($bn), 2013
Figure 4: Epilepsy Therapeutics, Lamictal, Global, Revenue ($m), 2009–2013
Figure 5: Epilepsy Therapeutics, Keppra, Global, Revenue ($bn), 2009–2013
Figure 6: Epilepsy Therapeutics, Zonegran, Global, Revenue ($m), 2009–2013
Figure 7: Epilepsy Therapeutics, Vimpat, Global, Revenue ($m), 2009–2013
Figure 8: Epilepsy Therapeutics, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013
Figure 9: Epilepsy Therapeutics, Global, Overall Pipeline Analysis, 2013
Figure 10: Epilepsy Therapeutics, Global, Pipeline Analysis, by Mechanism of Action, 2013
Figure 11: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Failure Rate, 2013
Figure 12: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Size, 2013
Figure 13: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Duration, 2013
Figure 14: Epilepsy Therapeutics, Major Developed Markets, Treatment Usage Pattern and Market Size, 2012–2019
Figure 15: Epilepsy Therapeutics, US, Treatment Usage Pattern, ACoT and Market Size, 2012–2019
Figure 16: Epilepsy Therapeutics, Top Five EU Countries, Treatment Patterns (‘000), 2012–2019
Figure 17: Epilepsy Therapeutics, Top Five EU Countries, Annual Cost of Treatment ($), 2012–2019
Figure 18: Epilepsy Therapeutics, Top Five EU Countries, Market Size ($m), 2012–2019
Figure 19: Epilepsy Therapeutics, Japan, Treatment Usage Pattern, ACoT and Market Size, 2012–2019
Figure 20: Epilepsy Therapeutics, Canada, Market Size, 2012–2019
Figure 21: Epilepsy Therapeutics, Deals by Region, Value and Year, 2006–2013
Figure 22: Epilepsy Therapeutics, Deals by Molecule Type and Mechanism of Action, 2006–2013
Figure 23: Epilepsy Therapeutics, Co-development Deals, Territory, 2006–2013
Figure 24: Epilepsy Therapeutics, Licensing Deals, by Territory, 2006–2013
Figure 25: GBI Research Market Forecasting Model

Upcoming Reports:

Cellulose Plastics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020
By - Transparency Market Research
Cellulose plastics are bioplastics manufactured using cellulose or derivatives of cellulose. Cellulose plastics are manufactured using softwood trees as the basic raw material. Barks of the tree are separated and can be used as an energy source in the production. To segregate cellulose fiber from the tree, the tree is cooked or heated in a digester. Resins and lignins are produced as a byproduct in the digester. The byproducts can be used as a fuel or as a feedstock in the production of other chemical products. The pulp such produced is comprises hemicelluloses and alpha cellulose....
High Performance Thermoplastics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020
By - Transparency Market Research
High performance thermoplastics mainly comprise engineering plastics with high performance standards. Some of the major product types for high performance engineering plastics include polycarbonate, polyamide, nylon 66 and PEEK (Polyether Ether Ketone) among others.  Polyamide is among dominant high performance thermoplastic with applications in various end user industries including automotive, electronics, construction, sports equipment and other consumer goods. Polyamide, also known as nylon occurs in nature in form of silk and wool and can be produced artificially through...
Cognitive Assessment And Training Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Cognitive assessment and training is a formal assessment of one’s psychological functions and speed of information processing. This method of assessment helps an individual in assessing, defining and focusing on individual needs more efficiently. The analysis after cognitive assessment can be useful for various functions such as cognitive training of individuals, early detection of dementia among population and sports management. Based on the statistics provided by Alzheimer's Disease International, approximately 44.4 million people are suffering from dementia worldwide, as of 2013;...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Effective Liver Fat Detection Via Magnetic Resonance
Sep 18, 2014  
The issue of excess body weight has several adverse effects. Fat accumulation affects the internal organs as well, one of them being the liver. Hepatic Steatosis is a condition that causes fibrosis, cirrhosis, and inflammation due to fat deposits in the liver. Hitherto, hepatic biopsy has been the most popular technique for diagnosing hepatic fat. It is way more precise in determining the fat...
Philips App-enabled Devices for Pain Relief
Sep 18, 2014  
PulseRelief and Blue Touch are the two latest pain relief devices developed by Philips. These devices consist of app-enabled tools which are managed by iPads or iPhones.  These days a lot of importance is being given to pain management and not just exploring drug options for pain relief. Many suffer from chronic pain that after a point of time begins to affect their lifestyles,...
Effects of Refinery Project on Barrel Prices
Sep 18, 2014  
According to the electronic newsletter issued by the California Independent Petroleum Association on Monday, the refinery project poses major economic questions regarding bringing extra crude barrels into the California market. This will affect the local crude prices in the state.  The oil-by-rail project of Alon USA Energy Inc. on Rosedale Highway stirs several questions...
AWU to Bid Renewable Energy Target Reforms
Sep 17, 2014  
The Australian Workers Union has asked for exemptions for the aluminum industry from the Renewable Energy Target. This is speculated to place increased pressure on Labor to draw up a bipartisan deal with the Coalition regarding amendments to the scheme. Scott McDine, the national secretary for AWU has stated the Renewable Energy Target, if it progresses in its current state, would...
James White Drinks Introduces New Look in its Apple Juice Range
Sep 17, 2014  
James White Drinks – premium fruit and vegetable juice maker has introduced a new and fresh look to its Classics English Apple Juice range. The brand has launched the range in time for the Christmas market season which is due in a few months.  Sourced from the English orchards featuring a richly-fine taste as perfect as a non-alcoholic alternative to wine products, this has...